nsc 674495 profile

NSC 674495: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	384525
CHEMBL ID	11825
SCHEMBL ID	1326042
MeSH ID	M0337756

Synonym
smr001565831
BB 0245167
NCI60_026383
mls002702269 ,
NSC674495 ,
nsc-674495
benzothiazole, 2-(4-amino-3-methylphenyl)-
benzenamine, 4-(benzothiazol-2-yl)-2-methyl-
BAS 06856403
4-benzothiazol-2-yl-2-methyl-phenylamine
df 203
2-(4-amino-3-methylphenyl)benzothiazole
nsc 674495
df-203
4-(1,3-benzothiazol-2-yl)-2-methylaniline
STK027735
bdbm50141278
4-benzothiazol-2-yl-2-methyl-phenyl amine
4-(3h-1lambda4-benzothiazol-2-yl)-2-methyl-phenylamine
4-(benzo[d]thiazol-2-yl)-2-methylbenzenamine
cid_384525
AKOS000108517
CHEMBL11825 ,
BBL008089
SCHEMBL1326042
178804-04-1
benzenamine, 4-(2-benzothiazolyl)-2-methyl-
CCG-35258
4-(benzo[d]thiazol-2-yl)-2-methylaniline
2-(4'-amino-3'-methylphenyl)benzothiazole
HMS3433D11
DTXSID30327656
mfcd00950805
SR-01000319885-1
sr-01000319885
[4-(1,3-benzothiazol-2-yl)-2-methylphenyl]amine
VS-01825
bm8 ,
4-(1,3-benzothiazol-2-yl)-2-methyl-aniline
EN300-231774
PD011737

Excerpt	Reference	Relevance
"A series of water-soluble L-lysyl- and L-alanyl-amide prodrugs of the lipophilic antitumor 2-(4-aminophenyl)benzothiazoles has been synthesized to address formulation and bioavailability issues related to the desired parenteral administration of the chosen clinical candidate."	( Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs. Hutchinson, I; Jennings, SA; Stevens, MF; Vishnuvajjala, BR; Westwell, AD, 2002)	0.31

Excerpt	Relevance	Reference
"0 microg/ml, and was applied to monitor the plasma concentration of MAB in a rat dosed with 25 mg/kg as a 1 min intravenous infusion."	( Analysis of 2-(3-methyl-4-aminophenyl)-benzothiazole (NSC 674495) in plasma by gas chromatography with mass-selective detection. Bramhall, C; Buckley, J; Daw, TW; Phillips, LR; Stinson, SF, 1999)	0.55
" The biphasic dose-response relationship characteristically shown by the benzothiazole series against sensitive cell lines was exhibited by the 4- and 6-fluoro-benzothiazoles (10b,d) but not by the 5- and 7-fluoro-benzothiazoles (10h,i)."	( Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. Bradshaw, TD; Browne, HL; Chua, MS; Hutchinson, I; Stevens, MF; Trapani, V; Westwell, AD, 2001)	0.31

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	89.1251	0.6310	35.7641	100.0000	AID504339
acid sphingomyelinase	Homo sapiens (human)	Potency	25.1189	14.1254	24.0613	39.8107	AID504937
glp-1 receptor, partial	Homo sapiens (human)	Potency	7.9433	0.0184	6.8060	14.1254	AID624417
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	3.1623	0.1000	20.8793	79.4328	AID588456
ClpP	Bacillus subtilis	Potency	1.2589	1.9953	22.6730	39.8107	AID651965
TDP1 protein	Homo sapiens (human)	Potency	21.8369	0.0008	11.3822	44.6684	AID686978; AID686979
Smad3	Homo sapiens (human)	Potency	0.1122	0.0052	7.8098	29.0929	AID588855
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	100.0000	0.5318	15.4358	37.6858	AID504845
chromobox protein homolog 1	Homo sapiens (human)	Potency	79.4328	0.0060	26.1688	89.1251	AID540317
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	2.0596	0.0041	9.9848	25.9290	AID504444
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	33.5278	5.8048	36.1306	65.1308	AID540253; AID540263
snurportin-1	Homo sapiens (human)	Potency	33.5278	5.8048	36.1306	65.1308	AID540253; AID540263
GTP-binding nuclear protein Ran isoform 1	Homo sapiens (human)	Potency	22.3872	5.8048	16.9962	25.9290	AID540253
geminin	Homo sapiens (human)	Potency	19.4763	0.0046	11.3741	33.4983	AID624296; AID624297
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	17.7828	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)	IC50 (µMol)	40.0000	0.0600	0.0600	0.0600	AID102975
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Nuclear hormone receptor family member daf-12	Caenorhabditis elegans	EC50 (µMol)	67.6490	4.2360	4.2360	4.2360	AID743038
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
positive regulation of cytokine production	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
positive regulation of cytokine-mediated signaling pathway	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
phospholipid metabolic process	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
phosphatidic acid biosynthetic process	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
epidermis development	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
response to xenobiotic stimulus	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
CDP-diacylglycerol biosynthetic process	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
triglyceride biosynthetic process	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
1-acylglycerol-3-phosphate O-acyltransferase activity	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endoplasmic reticulum	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
endoplasmic reticulum membrane	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
plasma membrane	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
specific granule membrane	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
endoplasmic reticulum	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (96)

Assay ID	Title	Year	Journal	Article
AID201019	Growth inhibition of the SR leukemia cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID202174	Growth inhibition of the SK-MEL-5 Melanoma cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID42300	Growth inhibition of the BT-549 Breast cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID8860	Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID93637	Growth inhibition against ovarian cancer cell line IGROV1	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID201812	Growth inhibition of the SK-MEL-2 Melanoma cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID201977	Growth inhibition of the SK-MEL-28 Melanoma cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID259223	Antiproliferative activity against human breast cancer cell line MCF7	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines.
AID200955	Growth inhibition of the SF-268 CNS cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID143486	Growth inhibition of the NCI/ADR-RES Breast cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID57893	Growth inhibition of the DU-145 Prostate cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID92292	In vitro concentration to reduce colony formation of human tumor xenografts to 30% of the control	1999	Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3	Antitumor benzothiazoles. 7. Synthesis of 2-(4-acylaminophenyl)benzothiazoles and investigations into the role of acetylation in the antitumor activities of the parent amines.
AID105217	Growth inhibition of the MDA-ME-231/ATCC Breast cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID8230	Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID200487	Growth inhibition of the SNB19 CNS cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID143050	Growth inhibition of the NCI-H460 non-small cell lung cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID497352	Cell cycle arrest in human BCC cells assessed as accumulation at sub G1 phase at 4 uM incubated for 4 hrs followed by 1 J/cm'2 UV irradiation measured after 24 hrs by annexin V/propidium iodide-based flow cytometry	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Synthesis, and biological evaluation of 2-(4-aminophenyl)benzothiazole derivatives as photosensitizing agents.
AID94856	Growth inhibition of the KM12 colon cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID156197	Growth inhibition of the PC-3 Prostate cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID92289	Clonal growth inhibition by the compound at at a concentration of 10(ug/mL) in human tumor xenografts in vitro. active, T/C < 30%; activity value is 2/22	1999	Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3	Antitumor benzothiazoles. 7. Synthesis of 2-(4-acylaminophenyl)benzothiazoles and investigations into the role of acetylation in the antitumor activities of the parent amines.
AID145775	Growth inhibition of the OVCAR-8 Ovarian cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID85238	Growth inhibition of the Hs 578.T Breast cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID79808	Growth inhibition against colon cancer cell line HCC2998; not tested	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID67447	Growth inhibition of the EKVX non-small cell lung cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID78643	Growth inhibition of the HCT-15 colon cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID80855	Growth inhibition of the HCT116 colon cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID215131	Growth inhibition of the UO-31 Renal cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID46468	Growth inhibition of the COLO-205 colon cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID19199	Log P (Octanol:buffer pH 7.4)	2001	Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8	Antitumour benzothiazoles. Part 15: The synthesis and physico-chemical properties of 2-(4-aminophenyl)benzothiazole sulfamate salt derivatives.
AID102445	Growth inhibition against breast cancer line MCF-7	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID93628	Growth inhibition of the UACC-62 Ovarian cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID259225	Antiproliferative activity against human colon cancer cell line KM12	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines.
AID102556	Growth inhibition of the MALME-3M Melanoma cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID104082	In vitro cytotoxicity against MCF-7 human mammary carcinoma cells	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID201119	Growth inhibition of the SF-295 CNS cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID43864	Growth inhibition of the CCRF-CEM leukemia cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID101526	Growth inhibition of the M14 Melanoma cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID202982	Growth inhibition of the SK-OV-3 Ovarian cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID201298	Growth inhibition of the SF-539 CNS cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID105218	Growth inhibition of the MDA-ME-435 Breast cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID145189	Growth inhibition of the NCI-H322M non-small cell lung cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID167421	Growth inhibition of the RXF-393 Renal cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID145085	Growth inhibition against non-small cell lung cancer cell line NCI-H266	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID209039	Growth inhibition against cancer cell line TH-10	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID145615	Growth inhibition against ovarian cancer cell line OVCAR-4	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID105242	Growth inhibition of the MDA-N Breast cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID102101	In vitro antitumor activity against MCF-7 carcinoma cell line.	1999	Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3	Antitumor benzothiazoles. 7. Synthesis of 2-(4-acylaminophenyl)benzothiazoles and investigations into the role of acetylation in the antitumor activities of the parent amines.
AID96332	Growth inhibition of the K-562 leukemia cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID259226	Antiproliferative activity against human colon cancer cell line HCC2998	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines.
AID92284	Clonal growth inhibition by the compound at at a concentration of 1(ug/mL) in human tumor xenografts in vitro. active, T/C < 30%.Sensitive cell lines are lung adrenocarcinoma 289 and mammary MCF-7; activity value is 2/22	1999	Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3	Antitumor benzothiazoles. 7. Synthesis of 2-(4-acylaminophenyl)benzothiazoles and investigations into the role of acetylation in the antitumor activities of the parent amines.
AID102975	Inhibitory concentration against human lysophosphatidic acid acyltransferase-beta (LPAAT-beta) expressed in Sf9 insect cell membranes	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Synthesis and SAR of 2-arylbenzoxazoles, benzothiazoles and benzimidazoles as inhibitors of lysophosphatidic acid acyltransferase-beta.
AID83780	Growth inhibition of the HT-29 colon cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID209387	Growth inhibition of the TK-10 Renal cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID28914	log P value in octanol:buffer at pH 7.4	2002	Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3	Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs.
AID214762	Growth inhibition of the UACC-62 Melanoma cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID28913	log P value in cyclohexane:buffer at pH 7.4	2002	Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3	Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs.
AID144774	In vitro antitumor activity against carcinoma cell lines by 6-day assay	1999	Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3	Antitumor benzothiazoles. 7. Synthesis of 2-(4-acylaminophenyl)benzothiazoles and investigations into the role of acetylation in the antitumor activities of the parent amines.
AID200467	Growth inhibition of the SN12C Renal cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID28982	Delta logP	2002	Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3	Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs.
AID214243	Growth inhibition of the U251 CNS cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID143348	Growth inhibition of the NCI-H522 non-small cell lung cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID10031	Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID144773	In vitro antitumor activity against carcinoma cell lines by 2-day assay	1999	Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3	Antitumor benzothiazoles. 7. Synthesis of 2-(4-acylaminophenyl)benzothiazoles and investigations into the role of acetylation in the antitumor activities of the parent amines.
AID79792	Growth inhibition of the HCC2998 colon cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID144652	Mean GI50 values are recorded over the NCI 60-cell panel.	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID101769	Growth inhibition of the MCF-7 Breast cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID8270	Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID144944	Growth inhibition of the NCI-H226 non-small cell lung cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID259224	Antiproliferative activity against human breast cancer cell line MDA468	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines.
AID200673	Growth inhibition of the SNB-75 CNS cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID81516	Growth inhibition of the HOP-62 non-small cell lung cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID92283	Clonal growth inhibition by the compound at at a concentration of 0.1(ug/mL) in human tumor xenografts in vitro. active, T/C < 30%; activity value is 2/22	1999	Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3	Antitumor benzothiazoles. 7. Synthesis of 2-(4-acylaminophenyl)benzothiazoles and investigations into the role of acetylation in the antitumor activities of the parent amines.
AID100701	Growth inhibition of the LOX IMVI Melanoma cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID143181	Growth inhibition against non-small cell lung cancer cell line NCI-H460	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID145602	Growth inhibition of the OVCAR-4 Ovarian cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID19198	Log P (Cyclohexane:buffer pH 7.4)	2001	Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8	Antitumour benzothiazoles. Part 15: The synthesis and physico-chemical properties of 2-(4-aminophenyl)benzothiazole sulfamate salt derivatives.
AID145750	Growth inhibition against ovarian cancer cell line OVCAR-5	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID201851	Growth inhibition of the SW-620 colon cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID104117	In vitro antitumor activity against MDA-468 carcinoma cell line.	1999	Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3	Antitumor benzothiazoles. 7. Synthesis of 2-(4-acylaminophenyl)benzothiazoles and investigations into the role of acetylation in the antitumor activities of the parent amines.
AID81665	Growth inhibition of the HL-60(TB) leukemia cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID210123	Growth inhibition of the T-47D Breast cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID214594	Growth inhibition of the UACC-257 Melanoma cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID105485	Growth inhibition of the MOLT-4 leukemia cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID209978	Growth inhibition against breast cancer line T-47-D	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor benzothiazoles. 14. Synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles.
AID145060	Growth inhibition of the NCI-H23 non-small cell lung cancer cell line for 2-day in vitro assay.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	3 (14.29)	18.2507
2000's	14 (66.67)	29.6817
2010's	3 (14.29)	24.3611
2020's	1 (4.76)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (9.52%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (90.48%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
halothane [no description available]	2.01	1	haloalkane; organobromine compound; organochlorine compound; organofluorine compound	inhalation anaesthetic
dehydrothio-4-toluidine dehydrothio-4-toluidine: structure in first source	2.05	1
thiazoles [no description available]	5.22	9	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
alpha-naphthoflavone alpha-naphthoflavone: inhibits P4501A1 and P4501A2; stimulates some activities of P4503A4. alpha-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the h side of flavone. A synthetic compound, it is an inhibitor of aromatase (EC 1.14.14.14).	2	1	extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound	aryl hydrocarbon receptor agonist; aryl hydrocarbon receptor antagonist; EC 1.14.14.14 (aromatase) inhibitor
2-(4-aminophenyl)benzothiazole 2-(4-aminophenyl)benzothiazole: an agent with selective profile of in vitro anti-tumour activity; structure in first source	4.02	4
5f-203 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole: structure in first source	3.81	3
gw 610 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole: has antineoplastic activity; structure in first source	2.03	1
nsc 710305 Phortress: structure in first source	3.52	2
ct-32228 CT-32228: CT-32212 is the inactive isomer of CT-32228 used as a control; structure in first source	2.02	1

Condition	Relationship Strength	Studies
Breast Cancer [description not available]	8.11	5
Breast Neoplasms Tumors or cancer of the human BREAST.	3.11	5
Cancer of Colon [description not available]	2.03	1
Cancer of Lung [description not available]	2.03	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.03	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.03	1
Carcinoma, Basal Cell, Pigmented [description not available]	2.05	1
Carcinoma, Basal Cell A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)	2.05	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Cancer of Ovary [description not available]	2.01	1
Experimental Mammary Neoplasms [description not available]	2.01	1
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.01	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2	1
Benign Neoplasms [description not available]	2.01	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.01	1

nsc 674495

Description

Cross-References

Synonyms (41)

Research Excerpts

Bioavailability

Dosage Studied

Protein Targets (18)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (26)

Molecular Functions (11)

Ceullar Components (13)

Bioassays (96)

Research

Studies (21)

Study Types

nsc 674495

Description

Cross-References

Synonyms (41)

Research Excerpts

Bioavailability

Dosage Studied

Protein Targets (18)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (26)

Molecular Functions (11)

Ceullar Components (13)

Bioassays (96)

Research

Studies (21)

Study Types

Related Drugs (9)

Related Conditions (16)